Merck KGaA Boosts Bioprocessing with JSR Life Sciences' Protein A Tech
Merck KGaA has agreed to acquire the chromatography business of JSR Life Sciences, a move that will bolster its position in the bioprocessing market and strengthen its commitment to monoclonal antibody production technologies. The deal, expected to close by the end of the second quarter of 2026, will bring advanced Protein A chromatography capabilities to Merck KGaA's portfolio.
JSR Life Sciences, led by President and Representative Director Eiji Takamoto, is renowned for its AmsphereTM A3 and AmsphereTM A+ Protein A resins. These resins are highly effective in purifying a wide range of monoclonal antibodies. The acquisition will enable customers to enhance the speed, efficiency, and reliability of antibody therapy production.
The chromatography business of JSR Life Sciences, based in Belgium with over 50 employees, will expand MilliporeSigma's downstream processing portfolio. This will position JSR Life Sciences' innovative AmsphereTM Protein A technologies for greater global impact under Merck KGaA's platform. The acquisition supports more efficient and scalable production of biopharmaceutical therapies, including monoclonal antibodies. JSR Life Sciences currently supplies chromatography solutions to pharmaceutical and biotech manufacturers worldwide.
The acquisition of JSR Life Sciences' chromatography business by Merck KGaA is set to strengthen Merck KGaA's position in the bioprocessing market. It will expand its portfolio, enhance production capabilities, and enable greater global impact for JSR Life Sciences' innovative Protein A technologies. The transaction is expected to close in the second quarter of 2026.
Read also:
- Delaware's Multilingual Learners Surge to 13%, Outpacing Funding and Teacher Support
- AI Boosts Post-Quantum Cryptography for Secure Transportation Systems
- Hesse Delegation Heads to Finland to Learn from Immigration Integration Success
- Hessian Minister Leads Delegation to Finland for Labor Market Exchange
